That comes after the third and final vaccination with the investigational treatment in Phase 1.
It also says the first participant was dosed in the Phase 2 dose-confirmation study.
The company says it's actively preparing for a Phase 3 pivotal study to evaluate efficacy of mRNA-1647 against primary CMV infection.
It will discuss the data in a conference call tomorrow at 8 a.m. ET.
Now read: Aclaris +20% on positive ATI-450 data »
Try Seeking Alpha PREMIUM for unlimited analysis on MRNA